<DOC>
	<DOCNO>NCT01837420</DOCNO>
	<brief_summary>This study examine safety efficacy subject moderate severe psoriasis , measure Psoriasis Area Severity Index ( PASI ) , Body Surface Area ( BSA ) , Dermatology Life Quality Index ( DLQI ) assessment .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety VB-201 Patients With Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Male female subject , ≥18 ≤75 year age , diagnosis chronic plaque psoriasis least 6 month prior screen ; Plaque psoriasis cover 10 % 30 % body surface area ( BSA ) ; PASI severity moderate severe , score least 10 high 20 . The subject present psoriasis predominantly guttate , erythrodermic , inverse , pustular palmoplantar unstable form psoriasis ; Previously fail ( due lack efficacy ) treatment least one systemic biologic agent psoriasis ( e.g . ustekinumab , adalimumab , etanercept , etc ) ; The subject undergone washout period sufficient duration follow treatment Baseline : Topical psoriasis treatment : 2 week ; Systemic ( nonbiologic ) psoriasis treatment : 4 week 5 halflives ( whichever longer ) ; Biologic psoriasis treatment : 8 week 5 half life ( whichever longer ) ; Phototherapy : 4 week ; The subject anticipate get enough ultraviolet light study ( e.g . sunbathe ; tan salon , etc . ) cause psoriasis improve ; History cancer , exception skin cancer .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>